Effect of novel antimicrobial blue light-emitting optical fiber on vancomycin-resistant <i>Enterococcus faecium</i> and carbapenemase-producing <i>Klebsiella pneumoniae</i>

Periprosthetic joint infections (PJIs), particularly those caused by multidrug-resistant organisms (MDROs), remain a major therapeutic challenge. Antimicrobial blue light (ABL) offers a promising non-antibiotic approach, inducing bacterial killing through photoexcitation of endogenous chromophores and subsequent reactive oxygen species generation. However, conventional single-point illumination systems are limited by uneven light distribution and poor penetration, restricting their use to superficial infections. We evaluated a novel isotropic optical fiber designed to overcome these geometric and optical constraints. The fiber was tested against vancomycin-resistant <i>Enterococcus faecium</i> (VR-Ef) and carbapenemase-producing <i>Klebsiella pneumoniae</i> (CP-Kp) in time-to-kill assays under low-power (20.1 mW mm<sup>-1</sup>) and high-power (40.3 mW mm<sup>-1</sup>) conditions over 60 min. Bacterial counts (CFU per mL) were determined at 0, 10, 20, 30, and 60 min. A one-way analysis of variance (ANOVA) with Tukey's post hoc test assessed time-dependent reductions; a two-way ANOVA evaluated the combined effects of illumination power and exposure time. ABL exposure resulted in time- and intensity-dependent bacterial reduction in both strains. Significant CFU reductions occurred from 30 min onward under high-power ABL (HP-ABL) and after 60 min under low-power ABL (LP-ABL) for both VR-Ef and CP-Kp ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>p</mml:mi> <mml:mo><</mml:mo> <mml:mn>0.001</mml:mn></mml:mrow> </mml:math> ). The two-way ANOVA revealed significant main and interaction effects of illumination power and exposure time (all <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>p</mml:mi> <mml:mo><</mml:mo> <mml:mn>0.001</mml:mn></mml:mrow> </mml:math> ). Although bactericidal thresholds ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mo>≥</mml:mo> <mml:mn>3</mml:mn> <mml:msub><mml:mi>log⁡</mml:mi> <mml:mn>10</mml:mn></mml:msub> </mml:mrow> </mml:math> reduction) were not reached, bacterial killing increased markedly with higher power and longer exposure. This novel isotropic optical fiber enables uniform intraluminal ABL delivery, potentially extending blue-light therapy from superficial to deep surgical infections such as PJIs. Further optimization of illumination parameters and potential integration with photosensitizers may enhance its antimicrobial efficacy and clinical applicability.

Authors

Institutions

Publication Details

Journal
Journal of Bone and Joint Infection
Published
2025-12-09
DOI
https://doi.org/10.5194/jbji-10-561-2025
Citations
1
Primary Topic
Photodynamic Therapy Research Studies
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of novel antimicrobial blue light-emitting optical fiber on vancomycin-resistant Enterococcus faecium and carbapenemase-producing Klebsiella pneumoniae

Santiago A. Lozano‐Calderón, Barbara Körber-Irrgang, Hilmar Wisplinghoff, Antonia F. Chen et al.
1 citations
Journal of Bone and Joint Infection
Photodynamic Therapy Research Studies
1.52
article

Effect of novel antimicrobial blue light-emitting optical fiber on vancomycin-resistant Enterococcus faecium and carbapenemase-producing Klebsiella pneumoniae

Santiago A. Lozano‐Calderón, Barbara Körber-Irrgang, Hilmar Wisplinghoff, Antonia F. Chen, Megan H. Goh, Nathalie Jazmati, Robert A. Rabiner, Lucy L. Hederick
article en
1 citations

Abstract

Periprosthetic joint infections (PJIs), particularly those caused by multidrug-resistant organisms (MDROs), remain a major therapeutic challenge. Antimicrobial blue light (ABL) offers a promising non-antibiotic approach, inducing bacterial killing through photoexcitation of endogenous chromophores and subsequent reactive oxygen species generation. However, conventional single-point illumination systems are limited by uneven light distribution and poor penetration, restricting their use to superficial infections. We evaluated a novel isotropic optical fiber designed to overcome these geometric and optical constraints. The fiber was tested against vancomycin-resistant <i>Enterococcus faecium</i> (VR-Ef) and carbapenemase-producing <i>Klebsiella pneumoniae</i> (CP-Kp) in time-to-kill assays under low-power (20.1 mW mm<sup>-1</sup>) and high-power (40.3 mW mm<sup>-1</sup>) conditions over 60 min. Bacterial counts (CFU per mL) were determined at 0, 10, 20, 30, and 60 min. A one-way analysis of variance (ANOVA) with Tukey's post hoc test assessed time-dependent reductions; a two-way ANOVA evaluated the combined effects of illumination power and exposure time. ABL exposure resulted in time- and intensity-dependent bacterial reduction in both strains. Significant CFU reductions occurred from 30 min onward under high-power ABL (HP-ABL) and after 60 min under low-power ABL (LP-ABL) for both VR-Ef and CP-Kp ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>p</mml:mi> <mml:mo><</mml:mo> <mml:mn>0.001</mml:mn></mml:mrow> </mml:math> ). The two-way ANOVA revealed significant main and interaction effects of illumination power and exposure time (all <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>p</mml:mi> <mml:mo><</mml:mo> <mml:mn>0.001</mml:mn></mml:mrow> </mml:math> ). Although bactericidal thresholds ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mo>≥</mml:mo> <mml:mn>3</mml:mn> <mml:msub><mml:mi>log⁡</mml:mi> <mml:mn>10</mml:mn></mml:msub> </mml:mrow> </mml:math> reduction) were not reached, bacterial killing increased markedly with higher power and longer exposure. This novel isotropic optical fiber enables uniform intraluminal ABL delivery, potentially extending blue-light therapy from superficial to deep surgical infections such as PJIs. Further optimization of illumination parameters and potential integration with photosensitizers may enhance its antimicrobial efficacy and clinical applicability.

Journal of Bone and Joint InfectionVol. 10(6)
Providence Regional Medical Center Everett (US), Witten/Herdecke University (DE), Massachusetts General Hospital (US), Laboratory Dr. Wisplinghoff (DE), University Hospital Cologne (DE), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 12%
Photodynamic Therapy Research Studies
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.